N-Ethylhexedrone
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
N-Ethylhexedrone (2-(ethylamino)-1-phenylhexan-1-one) — hexen, hex-en — is a synthetic stimulant of the cathinone class. It works like cocaine, blocking the brain's DAT rather than forcing dopamine release — but its effects last considerably longer. This blockade causes dopamine and norepinephrine to build up in the synapse,[1][2] producing the focused, driven stimulation characteristic of dopamine-dominant stimulants.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Cocaine, Amphetamine, Methylphenidate +2 moreCocaine, Amphetamine, Methylphenidate, Synthetic cathinones, Other DAT/NET inhibitors show less
Synthesized in 1964 by Boehringer Ingelheim as a candidate appetite suppressant,[3] it was shelved for five decades with no pharmacological development. It resurfaced on European research chemical markets in 2015 and within two years had become the most frequently seized cathinone in the EU, Norway, and Turkey.[4] It is now Schedule I in the United States and controlled across most of Europe.
Subjective effects include euphoria, psychomotor activation, wakefulness, increased focus, and appetite suppression. The experience is a clean, driven stimulation — dopamine-dominant, without the empathogenic warmth of serotonin-releasing cathinones, closely resembling a longer-acting cocaine.[1] Compulsive redosing,[5] cardiovascular strain, insomnia, and post-use anhedonia — an inability to feel pleasure — are characteristic unwanted effects.
N-Ethylhexedrone carries moderate abuse liability[5] and significant acute toxicity, with deaths documented at blood concentrations as low as 145 ng/mL.[6] Its 19–28 hour half-life[7] means each redose builds on an unseen physiological load — cardiovascular and neurotoxic burden accumulates long after the high fades. No controlled human studies existed before 2025,[8] and the evidence base is primarily lab studies, animal models, and forensic case reports.
History[edit]
Discovery
N-Ethylhexedrone was synthesized in 1964 by Boehringer Ingelheim as part of a patent series exploring aminoketone derivatives for appetite suppression.[3] It emerged from the same research program that produced MDPV.[3] NEH attracted no further pharmacological interest for approximately five decades.
Market emergence
NEH surfaced on European research chemical markets in late 2015, first intercepted by Belgian Customs in November of that year.[3] The EMCDDA issued a formal early warning in February 2016 after notifications from Sweden, the Netherlands, France, Belgium, and Slovenia.[3] Within two years it had become the most frequently seized cathinone in the EU, Norway, and Turkey[4] — among the three most common substances in cathinone-related fatality reports from 2017–2020.[4]
Contemporary status
The United States permanently placed NEH in Schedule I in June 2022.[9] The WHO Expert Committee on Drug Dependence issued a Critical Review at its 47th meeting in 2023.[10] The first prospective observational study in humans was not published until 2025.[8]
The name hexen — by which N-Ethylhexedrone is most commonly known in drug culture — derives from a phonetic abbreviation of its chemical name (hex- from hexedrone, -en from N-ethyl). The term became standard on research chemical vendor sites and user forums from 2016 onward, largely displacing the clinical abbreviation NEH. The compound's rapid rise to Europe's most-seized cathinone cemented its reputation as the dominant second-wave stimulant cathinone after the scheduling of mephedrone and MDPV.
Chemistry[edit]
Structural class
N-Ethylhexedrone belongs to the cathinone family — stimulants built on the same backbone as amphetamine, with a ketone group added at the beta-carbon. Its systematic name is 2-(ethylamino)-1-phenylhexan-1-one, reflecting a six-carbon chain with a phenyl ring at one end and an N-ethyl group at the adjacent nitrogen.
Among related N-ethyl cathinones varying only in chain length, all function as dopamine-selective reuptake inhibitors,[2] with NEH's chain length placing it at the peak of DAT inhibition.
Molecular properties
| Molecular formula | C₁₄H₂₁NO |
| Molecular weight | 219.32 g/mol |
Values confirmed via PubChem.[11]
Pharmacology[edit]
Mechanism of action
NEH blocks the DAT (DAT) and NET (NET),[1][2][12] preventing these neurotransmitters from being cleared from the synapse. It is a blocker — it sits in the transporter and obstructs reuptake without being transported into the nerve cell. This is how cocaine works too; it differs from releasers like amphetamine, which force a rapid neurotransmitter flood out of storage.
NEH's selectivity follows DAT > NET > SERT[13] — dopamine blockade far exceeds serotonin blockade. This dopamine dominance explains its pronounced rewarding properties and distinguishes it from serotonin-releasing cathinones like mephedrone, which also produce empathogenic warmth. High dopamine selectivity is consistently linked to elevated abuse potential.[13]
Pharmacokinetics
The plasma half-life is estimated at 19–28 hours[7] — unusually long for a stimulant whose effects last only 2–5 hours. NEH was still detectable in plasma up to ten days after intoxication,[7] and repeated dosing during this window produces unpredictable accumulation. NEH is processed in the liver through ketone reduction, N-dealkylation, hydroxylation, and glucuronic acid conjugation.[14][7]
Neuroscience[edit]
Where it acts
NEH's dopamine reuptake blockade primarily engages the mesolimbic mesolimbic pathway — the connection from the ventral tegmental area to the nucleus accumbens that drives motivation and reward.[13] It fully substitutes for cocaine and methamphetamine in drug discrimination studies,[1] confirming it activates the same reward circuitry. The focus and mental acceleration users report are consistent with elevated dopamine in the prefrontal cortex, though no brain imaging data exist for NEH.
Neurotoxicity and neuroadaptation
In cell studies, NEH kills nerve cells and uniquely activates microglia — the brain's immune cells — triggering inflammatory changes not seen with structurally simpler cathinones.[5] All tested N-ethyl cathinones exceed methamphetamine's cell toxicity.[2] Whether these findings translate to human brain damage at typical doses is unknown.
Repeated high-potency dopamine blockade follows a predictable arc: euphoria gives way to compensatory downregulation and lower baseline dopamine, driving compulsive use. Animals show depression-like behavior after NEH withdrawal.[5] Repeated dosing of the structural analog NEP produces addiction-related molecular changes (ΔFosB) in the striatum,[15] and NEH likely produces the same.
Whether NEH's enantiomers differ in potency or neurotoxicity remains untested. The in vitro finding of unique microglial activation has not been confirmed in living animals — if replicated, it would suggest a neuroinflammatory risk distinct from other cathinones. No dose-response relationship has been characterized for any effect, and no long-term data exist on cognitive or structural brain changes from repeated use.
Subjective Effects[edit]
NEH delivers a focused, driven stimulation — clean energy without the empathogenic warmth of serotonin-active cathinones. The experience is sharpened motivation and elevated mood, with a powerful drive to continue. At higher doses, the compulsive redosing urge becomes the defining feature, persisting even as pleasure plateaus.
Among cathinones, NEH sits between the ultra-potent pyrrolidine-ring compounds (α-PVP, α-PHP) and the serotonin-releasing entactogens (mephedrone, methylone). The subjective profile most closely resembles a longer-acting cocaine[1] — comparable reward-circuit engagement with stimulant effects lasting roughly twice as long as an insufflated cocaine line.
Effect Grid
Clear stimulant effects establish themselves — euphoria, psychomotor activation, and pronounced wakefulness define the experience. Thought acceleration and focus enhancement are prominent, and motivation enhancement creates a driven, task-oriented mental state. Compulsive redosing urges begin to manifest at this level, reflecting NEH's high DAT selectivity.
Physical effects include noticeable increases in heart rate and blood pressure, appetite suppression, bruxism, and dry mouth. Excessive sweating and muscle tension may appear. Temperature dysregulation is possible but typically mild at this range.
This is the dose range used in the only published human observational study (20–40 mg insufflated spans common-to-strong). Subjective effects last 2–5 hours insufflated, but the 19–28 hour half-life means redosing accumulates unpredictably — each subsequent dose adds to a still-elevated baseline. Insomnia is likely for many hours after dosing.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Auditory hallucinations · External hallucinations · Shadow people
Dry mouth · Insomnia · Pupil dilation · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Physical fatigue · Restlessness · Bruxism · Dehydration sensation · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Bodily lightness · Breathing alteration · Headache · Nasal congestion · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Trembling · Vibrations / buzzing · Constipation · Dizziness · Involuntary body movements · Nystagmus (eye wobbles) · Vomiting · Tactile hallucination
Excessive sweating · Heart rate perception changes · Muscle tension · Physical fatigue · Restlessness · Bruxism · Dehydration sensation · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Bodily lightness · Breathing alteration · Headache · Nasal congestion · Nausea · Sexual arousal enhancement · Tingling / electric sensations · Trembling · Vibrations / buzzing · Constipation · Dizziness · Involuntary body movements · Nystagmus (eye wobbles) · Vomiting · Tactile hallucination
Motivation enhancement · Motivation suppression · Focus enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Information processing enhancement · Multiple thought streams · Pattern recognition enhancement · Thought loops · Thought organization · Creativity enhancement · Language enhancement · Memory enhancement · Cognitive impairment · Confusion · Thought disorganization · Delusions · Delirium
Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Information processing enhancement · Multiple thought streams · Pattern recognition enhancement · Thought loops · Thought organization · Creativity enhancement · Language enhancement · Memory enhancement · Cognitive impairment · Confusion · Thought disorganization · Delirium
Dysphoria · Anhedonia · Emotional lability · Mania
Disinhibition · Social connection · Flow state · Ego inflation · Depersonalization · Derealization
Depersonalization · Derealization
Timeline
Mild stimulation begins as alertness increases and attention sharpens. A faint body energy may be noticed.
Stimulation builds rapidly; euphoria emerges alongside rising heart rate and focus enhancement. Appetite suppression begins.
Full stimulant effects — euphoria, thought acceleration, wakefulness, and cardiovascular stimulation at maximum. Compulsive redosing urges are strongest here.
Gradual decline in euphoria and stimulation. Residual wakefulness, cardiovascular effects, and appetite suppression persist. Irritability or mild anxiety may emerge.
Residual insomnia, appetite suppression, and mild dysphoria. Cardiovascular effects may persist due to the 19–28 hour elimination half-life.
⚠ Do not drive or operate machinery for at least 8 hours after last dose — residual impairment from cardiovascular effects, fatigue, and potential anxiety may persist well beyond subjective offset.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- Cocaine · Amphetamine · Methylphenidate
Toxicity
Lethal dose
No lethal dose has been established for N-Ethylhexedrone in any species.[11] The lowest blood concentration in a confirmed fatality was 145 ng/mL.[6]
Fatal cases
Three analytically confirmed deaths involving NEH appear in published literature. A 21-year-old male who purchased NEH believing it was cocaine developed disorientation, aggression, body temperature above 41°C, heart rate above 160 bpm, and kidney failure, dying within hours (postmortem blood NEH: 145 ng/mL).[6] A second death involved combined NEH and the synthetic cannabinoid ADB-FUBINACA,[16] and a third was a polydrug death attributed primarily to the synthetic opioid U-47700, with NEH present alongside multiple other substances.[17]
A review of cathinone-related fatalities from 2017–2020 identified NEH among the three most frequently occurring substances in 75 reported deaths.[4]
Severe non-fatal toxicity
Three confirmed single-substance NEH intoxications required hospitalization — two patients needed mechanical ventilation, and one developed dangerously low blood sodium (SIADH).[7] NEH remained detectable in one patient for ten days. A confirmed case of severe toxicity from combined 3-HO-PCP and NEH has also been reported.[18]
Cardiovascular toxicity
The stimulant toxidrome includes severe rapid heart rate (>160 bpm), high blood pressure, and dangerously elevated body temperature.[6] Heart rhythm disturbances, heart attack, and stroke are mechanistically expected risks, consistent with cocaine and amphetamine class effects.inferred
Neurotoxicity
In cell studies, NEH kills nerve cells and activates brain immune cells (microglia) at lower concentrations than simpler cathinones.[5] It exceeds methamphetamine's cell toxicity,[2] and animals show depression-like behavior after withdrawal.[5] Whether these findings translate to human brain damage at typical doses is unknown.
Psychological risks
Paranoia, feelings of persecution, anxiety, and anhedonia have been documented during and after NEH intoxication.[7] Post-use depression — fatigue, lack of motivation, thought deceleration — is supported by clinical observation[7] and animal models.[5]
As a potent DAT blocker, NEH carries substantial risk for compulsive redosing and binge patterns. Animal studies show reward responses comparable to cocaine and methamphetamine,[5][1] and agitation and aggression occur in severe intoxication.[6]
Tolerance & dependence
Tolerance builds with repeated use; community estimates suggest a reset period of approximately 1.5 weeks,safety citation needed though this is unverified and distinct from the 19–28 hour pharmacokinetic half-life.[7]
Evidence for clinically relevant dependence includes reward-seeking in mice,[5] full substitution for cocaine and methamphetamine in drug discrimination tests,[1] addiction-related molecular changes (ΔFosB) following repeated dosing of the structural analog NEP,[15] and post-withdrawal depression-like behavior.[5] Cross-tolerance is expected with cocaine, amphetamine, methylphenidate, and other cathinones.[1]
Drug interactions
No substance-specific interaction studies have been published for NEH. The following are based on pharmacological mechanism and class-level evidence.[19]
Monoamine oxidase inhibitors
Combining NEH with MAOIs risks dangerous blood pressure spikes and potentially fatal neurotransmitter overload. NEH blocks norepinephrine clearance; MAOIs simultaneously block monoamine breakdown — together they drive neurotransmitter levels dangerously high.[19]
Serotonergic drugs
SSRIs, SNRIs, triptans, and tramadol combined with NEH create risk of serotonin syndrome — a potentially life-threatening response involving overheating, muscle rigidity, and seizures.[19] The tramadol–NEH combination is designated lethal and the MDMA–NEH combination dangerous; both are mechanistically plausible, though no confirming case reports have been published.safety citation needed
Opioids
A fatal polydrug case documents the lethal potential of cathinone-opioid-benzodiazepine combinations: NEH (58 ng/mL) alongside U-47700 (1470 ng/mL) and adinazolam.[17]
Other stimulants
Combining NEH with cocaine, amphetamines, or other cathinones produces additive cardiovascular burden. A fatal combination with the synthetic cannabinoid ADB-FUBINACA has been reported.[16]
Dissociatives
Severe acute toxicity from combined 3-HO-PCP and NEH has been analytically confirmed.[18]
Cardiovascular and psychiatric medications
NEH's stimulant effects may overwhelm blood pressure medications.[19] Combining it with antipsychotics risks competing dopamine effects and heart rhythm prolongation.[19]
Contraindications
No substance-specific contraindication studies exist. The following are inferred from NEH's pharmacological profile and clinical adverse events.inferred
Pre-existing heart conditions, high blood pressure, or rhythm abnormalities are absolute contraindications — NEH produces heart rates above 160 bpm and blood pressure spikes in severe cases.[6] Kidney impairment compromises clearance (half-life 19–28 hours) and increases susceptibility to kidney damage.[6] Liver impairment may prolong drug exposure.[7]
Seizure disorders, psychotic disorders, severe anxiety, and bipolar disorder are contraindicated — cathinones lower seizure threshold,[20] and NEH is documented to produce paranoia and agitation.[7] Major depressive disorder compounds the risk of post-use depressive episodes.[5] The report of dangerously low blood sodium (SIADH) following NEH intoxication[7] indicates particular risk for those with electrolyte disorders. No reproductive toxicity data exist; as a potent stimulant with documented hyperthermia, use during pregnancy carries presumed fetal risk.inferred
Harm Reduction[edit]
Forms & Identification
N-Ethylhexedrone is typically sold as a white to off-white crystalline powder, marketed as "hexen" or "hex-en." Reagent testing can confirm the broad cathinone class but cannot distinguish NEH from other cathinones. Quantitative analysis through a drug checking service is the only reliable identification.
Active doses are measured in tens of milligrams. A milligram-capable scale (0.001 g) is essential — volume measurement is unreliable, and the margin between desired and dangerous effects is poorly characterized.
Guidelines
- Weigh every dose on a milligram-capable scale — never estimate by eye or volume
- Start with the lowest reported active dose and wait at least 90 minutes before considering redosing
- Pre-set a firm dose limit before the session begins; compulsive redosing is the compound's defining behavioral risk
- Keep the total session supply limited — having more available is the strongest predictor of binge use
- Ensure access to water and a cool environment; body temperature regulation is impaired under stimulant load
- Do not use alone for the first time; have a sober person present or informed of your plans
- Avoid use within 24 hours of a previous session — the long half-life means the previous dose has not fully cleared
Set & Setting
NEH's dopamine-dominant stimulation amplifies existing mood states and environmental pressures. Anxious or paranoid baseline states can escalate rapidly under stimulant activation. Use in unfamiliar or high-stress environments increases the risk of agitation and paranoid ideation documented in clinical cases.
The 19–28 hour half-life means physiological stimulation persists far beyond perceived effects. Planning for extended inability to sleep, eat, or relax is essential — NEH is not compatible with next-day obligations.
Aftercare & integration. The comedown can include fatigue, depressed mood, difficulty concentrating, and lack of motivation — consistent with temporary dopamine depletion after sustained reuptake blockade. These effects may persist for several days given the drug's long half-life.
Prioritize sleep, hydration, and regular meals in the 48–72 hours following use. Avoid caffeine and other stimulants during recovery — they stress the same cardiovascular and neurochemical systems. If depressed mood or anhedonia persists beyond one week, consider consulting a healthcare professional — post-withdrawal depressive symptoms are documented in animal models of NEH use.
Recovery & Support
NEH's high DAT potency, confirmed reward-circuit engagement, and compulsive redosing patterns place it among the cathinones with the highest dependence risk. Inability to limit sessions, escalating doses, or significant post-use depression are warning signs.
Professional support options include addiction counseling, cognitive-behavioral therapy, and peer support groups experienced with stimulant dependence (such as SMART Recovery or stimulant-focused 12-step programs). Medical evaluation is recommended for anyone experiencing cardiovascular symptoms, persistent mood changes, or cognitive difficulties following repeated use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizures, loss of consciousness, body temperature hot enough to feel through clothing, uncontrollable agitation, or confusion that prevents communication all require immediate medical attention. These signs distinguish a medical emergency from ordinary stimulant discomfort.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool, quiet space
- 3. Remove excess clothing and apply cool (not ice-cold) water to the skin if body temperature is elevated
- 4. Place an unconscious person in the recovery position (on their side, airway clear)
- 5. Do not restrain a person unless they are in immediate danger of harming themselves — restraint can worsen hyperthermia
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (N-Ethylhexedrone / hexen), the approximate amount taken, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
N-Ethylhexedrone is controlled in most major jurisdictions, either through specific scheduling or broad novel psychoactive substance legislation targeting the cathinone class. The WHO Expert Committee on Drug Dependence issued a Critical Review at its 47th meeting in 2023.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporarily scheduled July 2019;[21] permanently placed in Schedule I effective June 2022[9] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Blanket prohibition on substances producing psychoactive effects by stimulating or depressing the CNS; effective May 26, 2016citation needed |
| Germany | Controlled under Neue-psychoaktive-Stoffe-Gesetz (NpSG) | Controlled since November 26, 2016; production, import for market placement, and commercial trading are criminal offences; simple possession prohibited but not criminally punishablecitation needed |
| Canada | Schedule I (Controlled Drugs and Substances Act) | All cathinones encompassed under broad chemical class schedulingcitation needed |
| Australia | Controlled substance (Office of Drug Control) | Listed by ODC; exact schedule not confirmed — likely Schedule 9 based on cathinone class controlscitation needed |
| European Union | Subject to EMCDDA early warning (February 2016) | Sweden, France, Belgium, Netherlands, and Slovenia among first to notify; most EU member states have enacted controls through national NPS legislation or analogue provisions[3] |
Legal status changes frequently and varies by jurisdiction. The information above reflects available sources and may not be current. This is not legal advice.
references
- [1]
- [2]
- [3]
- [4] ^abcdLa Maida N, Di Trana A, Giorgetti R, Tagliabracci A, Busardò FP, Huestis MA (2021) A Review of Synthetic Cathinone-Related Fatalities From 2017 to 2020 — Therapeutic Drug Monitoring doi:10.1097/ftd.0000000000000808
- [5] ^abcdefghijkde Mello-Sampayo C, Vaz AR, Henriques SC, Fernandes A, Paradinha F, Florindo P, Faria P, Moreira R, Brites D, Lopes A (2021) Designer Cathinones N-Ethylhexedrone and Buphedrone Show Different In Vitro Neurotoxicity and Mice Behaviour Impairment — Neurotoxicity Research doi:10.1007/s12640-020-00229-6
- [6]